Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Head Neck. 2019 Aug 22;41(11):3924–3932. doi: 10.1002/hed.25922

Table 2.

Selected characteristics of the RTOG protocol 9003 study population with a PSS-HN (N=744)

Age, median (IQR) 60 (53, 66)
Sex No. of Patients % of total
 Male 597 80.2
 Female 147 19.8
Race
 White 541 72.7
 Hispanic 40 5.4
 Black 145 19.5
 Other 12 1.6
Protocol RX
 standard 191 25.7
 HFX arm 195 26.2
 AFX-C arm 177 23.8
 AFX-S arm 181 24.3
Education
 Grade 1-8, or none 107 14.4
 Some high school 180 24.2
 High school graduate 211 28.4
 Some college/technical 208 28.0
Marital Status
 Married 370 49.7
 Not married 356 47.8
Smoking
 Non-smoker 72 9.7
 <20 pack years 86 11.6
 20-40 pack years 180 24.2
 >40 pack years 356 47.8
 Unknown, unanswered 50 6.7
Cancer site
 Oral cavity 76 10.2
 Oropharynx 441 59.3
 Hypopharynx 104 14.0
 Supraglottic larynx 123 16.5
KPS
 60 28 3.8
 70 76 10.2
 80 158 21.2
 90 347 46.6
 100 135 18.1
Tumor classification
 T1 43 5.8
 T2 202 27.2
 T3 277 37.2
 T4 222 29.8
Lymph node classification
 N0 158 21.2
 N1 150 20.2
 N2 349 46.9
 N3 87 11.7
Highest grade toxicity within 6 months post-treatment
 0-2 328 44.1
 3-5 416 55.9

Abbreviations: RTOG=radiation therapy oncology group, PSS-HN=Performance Status Scale for Head and Neck cancer patients, IQR=interquartile range, RX=radiation treatment, HFX=hyperfractionated, AFX-C=accelerated fractionated with concomitant boost, AFX-S=accelerated fractionated with a split